Change in FGF-2 circulating levels after arterial embolization in patients with bone metastases

Giuseppe Rossi, Manuela Salerno, Donatella Granchi, E. Cenni, Giancarlo Facchini, Nicola Baldini

Research output: Contribution to journalArticlepeer-review


Arterial embolization, aimed at the mechanical occlusion of tumor-feeding vessels, represents a satisfactory palliative therapy for bone metastases. In this study, we evaluated if the circulating levels of three factors related to the metastatic process change in response to embolization. Seven patients who underwent embolization of a single skeletal metastasis from carcinomas were analyzed prospectively. Circulating levels of Vascular Endothelial Growth Factor A (VEGF-A), Fibroblast Growth Factor 2 (FGF-2), and Tartrate-Resistant Acid Phosphatase-5b Isoform (TRACP5b) were evaluated before and after embolization at 1, 3, and 6 months. According to morphological and clinical evaluations, all the embolizations were successful. VEGF-A and TRACP5b did not show significant changes after the treatment. On the contrary, FGF-2 significantly decreased 1 month after the treatment. FGF-2 appears as a promising candidate for monitoring the efficacy of embolization in patients with osteolytic metastases.

Original languageEnglish
Pages (from-to)262-268
Number of pages7
Issue number2
Publication statusPublished - 2018


  • Angiogenesis
  • Bone metastases
  • FGF-2
  • Transcatheter arterial embolization

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Change in FGF-2 circulating levels after arterial embolization in patients with bone metastases'. Together they form a unique fingerprint.

Cite this